Weiding Wu

Shanghai Xinpu BioTechnology is a clinical-stage biotechnology company specializing in the development of personalized cancer immunotherapies, with a primary focus on mRNA-based neoantigen vaccines. The company leverages advanced genomic sequencing and bioinformatics to identify patient-specific tumor mutations and design tailored vaccines aimed at stimulating a robust T-cell response. Its lead programs include personalized mRNA vaccines for pancreatic cancer and other advanced solid tumors, often evaluated in combination with immune checkpoint inhibitors like pembrolizumab. Based in Shanghai, the company collaborates closely with leading academic institutions such as Shanghai Jiao Tong University and Ruijin Hospital to translate cutting-edge research into clinical applications.